Chimeric TherapeuticsCHMMF -96.67%13 3-Year RORE % is -30.33 as of Dec. 2025. GuruFocus rates CHMMF with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 1,290 Biotechnology companies, Chimeric Therapeutics ranks worse than 68.99% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Chimeric Therapeutics's 3-Year RORE % for the quarter that ended in Dec. 2025 was -30.33%.
The industry rank for Chimeric Therapeutics's 3-Year RORE % or its related term are showing as below:
CHMMF's 3-Year RORE % is ranked worse than 68.99% of 1290
companies
in the Biotechnology industry
Industry Median: -11.54
vs CHMMF: -30.33
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Chimeric Therapeutics 3-Year RORE % Related Terms
Chimeric Therapeutics 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Chimeric Therapeutics's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHMMF vs VRTX, REGN, ALNY: 3-Year RORE % Comparison
For the Biotechnology subindustry, Chimeric Therapeutics's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chimeric Therapeutics 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Chimeric Therapeutics's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
Chimeric Therapeutics (CHMMF) has a 3-Year RORE % of -30.33 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Chimeric Therapeutics and its competitors. According to the industry distribution chart, Chimeric Therapeutics ranks #890 out of 1290 companies in the Biotechnology industry, placing it in the top 69%.
Is Chimeric Therapeutics' 3-Year RORE % too high?
Chimeric Therapeutics' current 3-Year RORE % is -30.33. Based on the distribution chart, Chimeric Therapeutics ranks #890 out of 1290 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Chimeric Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Chimeric Therapeutics' 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chimeric Therapeutics ranks #890 out of 1290 companies for 3-Year RORE %. This places Chimeric Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Chimeric Therapeutics and its competitors. Chimeric Therapeutics's current 3-Year RORE % is -30.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chimeric Therapeutics stock overvalued right now?
Chimeric Therapeutics (CHMMF) has a current 3-Year RORE % of -30.33. The current 3-Year RORE % is -30.33. Chimeric Therapeutics' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Chimeric Therapeutics (CHMMF), the current 3-Year RORE % is -30.33 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.
13GF Score
Get the complete analysis for CHMMF
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHMMF has been successfully added to your 
